ImmunovantInc Return On Equity vs. Return On Asset
| IMVT Stock | USD 28.74 0.52 1.84% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (1.16) | Current Value (1.11) | Quarterly Volatility 0.25556617 |
For ImmunovantInc profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunovantInc to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunovantInc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunovantInc's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunovantInc over time as well as its relative position and ranking within its peers.
ImmunovantInc |
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ImmunovantInc Return On Asset vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmunovantInc's current stock value. Our valuation model uses many indicators to compare ImmunovantInc value to that of its competitors to determine the firm's financial worth. ImmunovantInc is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, ImmunovantInc's Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunovantInc by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunovantInc's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunovantInc's earnings, one of the primary drivers of an investment's value.ImmunovantInc Return On Asset vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
ImmunovantInc |
| = | -0.45 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
ImmunovantInc |
| = | -0.27 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
ImmunovantInc Return On Asset Comparison
ImmunovantInc is currently under evaluation in return on asset category among related companies.
ImmunovantInc Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunovantInc, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunovantInc will eventually generate negative long term returns. The profitability progress is the general direction of ImmunovantInc's change in net profit over the period of time. It can combine multiple indicators of ImmunovantInc, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 979.8 K | 1 M | |
| Operating Income | (450.00) | (472.50) | |
| Net Loss | -189.9 M | -180.4 M | |
| Income Before Tax | (450.00) | (472.50) | |
| Net Loss | (450.00) | (472.50) | |
| Net Loss | (450.00) | (472.50) | |
| Total Other Income Expense Net | -11.2 M | -10.7 M | |
| Income Tax Expense | 8.1 K | 8.5 K | |
| Net Interest Income | 8.7 M | 9.2 M | |
| Interest Income | 8.7 M | 9.2 M | |
| Non Operating Income Net Other | -227.7 K | -239.1 K | |
| Change To Netincome | 37.1 M | 39 M | |
| Net Loss | (1.29) | (1.35) | |
| Income Quality | 1.00 | 0.91 | |
| Net Income Per E B T | 1.00 | 1.10 |
ImmunovantInc Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmunovantInc. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunovantInc position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunovantInc's important profitability drivers and their relationship over time.
Use ImmunovantInc in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunovantInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunovantInc will appreciate offsetting losses from the drop in the long position's value.ImmunovantInc Pair Trading
ImmunovantInc Pair Trading Analysis
The ability to find closely correlated positions to ImmunovantInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunovantInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunovantInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunovantInc to buy it.
The correlation of ImmunovantInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunovantInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunovantInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunovantInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ImmunovantInc position
In addition to having ImmunovantInc in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 140 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for ImmunovantInc Stock analysis
When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
To fully project ImmunovantInc's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ImmunovantInc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ImmunovantInc's income statement, its balance sheet, and the statement of cash flows.